Sulfonylurea type 2 diabetes drugs have been linked to a higher long-term risk of an impaired awareness of hypoglycemic episodes. A recent study from Taiwan suggests that after 5 years of use, repeated hypoglycemic events can desensitize sulfonylurea users to the symptoms of hypoglycemia. This impairment of hypoglycemic awareness was compared with insulin use, which tapered off over time. The study, published in the Annals of Family Medicine, found that people taking sulfonylureas for 5 or more years were three times more likely to have impaired hypoglycemia awareness.
Sulfonylureas are a class of type 2 diabetes medications that work by stimulating beta cells in the pancreas to promote insulin production. They include drugs like Glipizide, Glimepiride, and Glyburide. While both sulfonylureas and insulin were associated with an increased risk of hypoglycemia in the short term, the study found that sulfonylureas led to a higher chance of impaired hypoglycemia awareness over time. Impaired awareness of hypoglycemia refers to a reduced capacity to detect when blood sugar levels drop too low due to repeated hypoglycemic episodes.
The study, conducted in Tainan City, Taiwan, involved 898 people with type 2 diabetes, with 65.1% on sulfonylureas and 41.0% on insulin. The researchers used standard measures like the Gold and Clarke questionnaires to assess impaired hypoglycemia awareness. Both sulfonylurea and insulin users experienced impaired awareness in the early years of treatment, but after 5 years, the incidence increased among sulfonylurea users while decreasing among those taking insulin.
According to endocrinology expert Jason Ng, MD, sulfonylureas may be preferred over insulin for patients with mildly elevated blood sugar levels who may not want daily injections. However, newer blood sugar control medications that work by different mechanisms are available and do not carry the same risk of hypoglycemia associated with sulfonylureas. It is important for individuals with type 2 diabetes to be aware of the symptoms of hypoglycemia, including tremors, sweats, dizziness, and changes in mental status, among others.
Regular blood glucose testing and retinal scans were found to be associated with lower rates of impaired hypoglycemia awareness in the study participants. While the study highlights the potential danger of hypoglycemia with sulfonylureas, there were limitations to the research, including the homogeneity of the study population and self-reported medical care. Establishing a causal link between sulfonylureas, insulin, and impaired hypoglycemia awareness was not within the scope of the study. Overall, it is essential for individuals with type 2 diabetes to communicate regularly with their healthcare provider to monitor their blood sugar levels and adjust their medication as needed.
